Immunotherapy that is based on adoptive transfer of T lymphocytes, which are genetically modified to express chimeric antigen receptors (CARs) that recognize tumor-associated antigens, has been demonstrated to be an efficient cancer therapy. Vascular endothelial growth factor receptor-1 (VEGFR-1), a vital molecule involved in tumor growth and angiogenesis, has not been targeted by CAR-modified T lymphocytes. In this study, we generated CAR-modified T lymphocytes with human VEGFR-1 specificity (V-1 CAR) by electroporation. V-1 CAR-modified T lymphocytes were demonstrated to elicit lytic cytotoxicity to target cells in a VEGFR-1-dependent manner. The adoptive transfer of V-1 CAR T lymphocytes delayed tumor growth and formation and inhibited pulmonary metastasis in xenograft models and such efficacies were enhanced by cotransfer of T lymphocytes that expressed interleukin-15 (IL-15). Moreover, V-1 CAR-modified T lymphocytes lysed primary endothelial cells and impaired tube formation, in vitro. These data demonstrated the antitumor and anti-angiogenesis ability of V-1 CAR-modified T lymphocytes. Our study provides the rationale for the clinical translation of CAR-modified T lymphocytes with VEGFR-1 specificity.
INTRODUCTION
T lymphocytes genetically engineered to express T cell receptors or chimeric antigen receptors (CARs) redirect the lymphocytes with tumor specificity. 1 As single-chain variable fragments (scFvs) mediate recognition of the tumor-associated antigens, CAR-engineered T lymphocytes lyse target tumor cells in a non-MHC-restricted manner in contrast to T cell receptorengineered T lymphocytes. 2 Genetically modified T lymphocytes to express CARs specific to different antigens, including CD20, 3 carcinoembryonic antigens 4 and ErbB2 5 have presented therapeutical potential. The adoptive transfer of T lymphocytes with CARs targeting to CD19 has been used clinically to treat lymphoma. [6] [7] [8] Anti-angiogenesis is a defined and efficient cancer therapy. Plenty of strategies have been developed to target vascular endothelial growth factor (VEGF) and its receptor (VEGFRs) to inhibit the formation of blood vessels. Adoptive transfer of genetically modified T lymphocytes, however, had never been exploited to inhibit angiogenesis of tumor until Chinnasamy et al. 9 initiated the usage of genetically engineered T lymphocytes to impair tumor vasculature through the recognition VEGFR-2. In the progression of solid tumors, the VEGFRs mediated neo-vascular system supply nutrients for the survival and proliferation of tumor cells. Despite VEGFR-1 and VEGFR-2 are aberrantly expressed at high levels on activated endothelial cells within tumor blood vessels, the biologic activity of these two receptors vary. VEGFR-1 has a greater (10-fold) binding ability to VEGF than VEGFR-2 but has weaker tyrosine kinase activity than VEGFR-2. 10 This determines VEGFR-1 as a regulator of the binding of VEGF to VEGFR-2, which prevents over-activation of VEGF/VEGFR-2 pathways. Therefore, VEGFR-1 is involved in the inhibition of vascular hyperplasia and the normalization of blood vessel function. 11, 12 The blockade of cytoplasmic tyrosine kinase activity of VEGFR-1 by small molecules and antibodies likely has a more modest efficacy than the direct cytotoxicity elicited by immunotherapies and antibodies conjugated with toxin. As a cancer therapy has proof-of-concept demonstration, adoptive transfer of genetically modified T lymphocytes, of which the killing activities is mediated by the cytotoxicity, is a good option for VEGFR-1-based cancer therapy.
VEGFR-1 is not exclusively expressed on vascular endothelial cells. It is also expressed in many tumor cells. Non-small lung carcinoma and breast cancer cells have high expression levels of VEGFR-1. 13, 14 Many tumor cells, such as A549, MDA-MB-231, MDA-MB 435, K562 and many cell lines of colon cancer express high levels of VEGFR-1. 15, 17 Non-endothelial expressed VEGFR-1 participates in many of the biological activities that are involved in the carcinogenesis, progression and metastasis of cancer. VEGFR-1 expressed on tumor cells binds to VEGF and placenta growth factor from the paracrine and autocrine pathways to support proliferation of cancer cells. In addition, VEGFR-1 promotes lung-specific metastasis through the induction of matrix metalloproteinase-9 in the premetastatic niche. 18 VEGFR-1 activation mediates nonmalignant cells, such as macrophages and stromal cells, to support the genesis and metastasis of tumors. 19 These findings indicate that VEGFR-1 is a preferred target for cancer therapy. As VEGFR-1 is expressed on both cancer cells and angiogenic cells, therapies targeting to VEGFR-1 potentiate an increased efficacy than therapies that only inhibits either tumor growth or angiogenesis. IMC-18F1, a full human neutralizing monoclonal antibody of VEGFR-1, showed an efficient growth inhibition of breast cancer xenografts and this monoclonal antibody is currently in a phase II clinical trial.
In this study, we designated a CAR with VEGFR-1 specificity and redirected the T lymphocytes by electroporation. The modified lymphocytes indicated specific cytotoxicity to cancer cells and primary endothelial cells in a VEGFR-1-dependent manner. The adoptive transfer of the modified T lymphocytes delayed tumor formation and effectively inhibited pulmonary metastasis of the xenografts. In addition, the modified T lymphocytes destroyed the angiogenic tubule formation, in vitro. Our data demonstrate that the T lymphocytes that were redirected with VEGFR-1 specificity can inhibit the growth of tumors through the killing of cancer cells and the impairment of vasculature. We provide a rationale for the application of adoptive cell immunotherapy based on the lymphocytes with VEGFR-1 specificity.
RESULTS

Generation of V-1 CAR T lymphocytes by nuclear electroporation
To design a CAR with VEGFR-1 affinity, we selected a scFv with high affinity to VEGFR-1 and a universal CAR construct 20 was ligated to scFv (Figures 1a and b ). An immunoglobulin G1 (IgG1) Fc ensures the spatial distance of the CARs from cell membrane, which is vital for the CARs to bind to antigens. 3 The transmembrane domain of CD4 (CD4-TM) is an anchor that facilitates, with the signaling from signal peptide of human interleukin 2 (Sp of IL-2), the expression of CARs on cell membrane. The CD3-z chain elicits a cytotoxic response when the CAR engages with its antigen. The CAR with VEGFR-1 specificity (V-1 CAR) was inserted into a pmaxCloning plasmid vector (Lonza, Allendale, NJ, USA). To generate CAR-modified T lymphocytes, we used Nucleofecotr II (Lonza) to transfect the T lymphocytes. Electroporation was performed when the percentage of CD3-positive lymphocytes was 495%, as determined by flow cytometry after anti-CD3/IL-2 stimulation as previously described. 21 The Nucleofector system is an efficient electroporation tool and is suitable for non-viral transfection of lymphocytes. [22] [23] [24] As shown in Figure 1c , nuclear electroporation of lymphocytes with a green fluorescent protein reporter gene within the backbone of the pmaxCloning vector indicated high transfection efficiency was obtained. V-1 CAR that is based on the same plasmid backbone also expressed at a substantial level in the transfected T lymphocytes (Figure 1d ). V-1 CAR expression was detected using an anti-CD-z antibody. Because the V-1 CAR construct included a CD3-z sequence (Figures 1a and b) , we detected a protein band with an expected molecular weight of 55kD. Endogenous CD3-z was detected in both transfected or untreated lymphocytes. Expression of V-1 CAR was further confirmed by flow cytometry (Figure 1e ). We exploited this system to express human IL-15 in lymphocytes, and a high level of IL-15 was detected in the supernatant by ELISA assay (Figure 1f) . As detected by the green fluorescent protein reporter, we can detect its expression within 2 weeks after the transfection (data not shown). These data indicate that the modified lymphocytes expressed high levels of the interested proteins and are feasible for additional functional analysis. V-1 CAR-modified T lymphocytes present specific cytotoxicity to VEGFR-1 positive cells VEGFR-1 expression is not restricted to tumor vasculature. It is also expressed on many tumor cells, such as colon cancer, breast cancer and lung adenocarcinoma. In this study, we selected three tumor cell lines, MDA-MB-231, A549 and Hela, and primary human Cr release assay, we demonstrated that V-1 CAR-modified T lymphocytes efficiently lysed the tumor cells in a manner that was dependent on VEGFR-1 expression level, which is coincided with our expectations (Figure 3b ). However, V-1 CAR-modified T lymphocytes lysed HUVECs at the level that is similar with MDA-MB 231 cells although the VEGFR-1 expression level of HUVEC is lower than that of MDA-MB 231. This may ascribe to the sensitive vulnerability of primary HUVEC cells as the basal lytic percentage is much higher than that of the tumor cells (Figure 3b) . Morphologically, the lytic activity of V-1 CAR-modified T lymphocytes was documented. As shown in Figure 3c , V-1 CAR-modified T lymphocytes were cocultured with A549 cells and these cells were stained by propidium iodide 48 h after coculture. The nuclei of A549 (blue arrow) and T lymphocytes (orange arrow head) were visualized. These nuclei of the two kinds of cells can be easily differed as the nuclei of A549 are of big size and the nuclei of T lymphocytes are smaller and thicker. Compared with the T lymphocytes modified with a blank vector plasmid (Blank Vector), the V-1 CAR-modified T lymphocytes (V-1) lysed A549 cells more efficiently as there were A549 nuclei; the proliferation of V-1 CAR-modified T lymphocytes was also observed because there were more V-1 CAR-modified T lymphocyte nuclei than the nuclei of T lymphocytes that were modified with the Blank Vector ( Figure 3c ). These data demonstrated that V-1 CAR-modified T lymphocytes are redirected with the killing activity of VEGFR-1 þ cells, which potentiates the antitumor and anti-angiogenic capacities of the modified T lymphocytes.
T lymphocytes expressing IL-15 enhance the cytotoxicity of V-1 CAR-modified T lymphocytes to A549 cells IL-15 is essential for the proliferation and activation of natural killer cells and CD8 þ T lymphocytes. 25 For adoptively transferred T lymphocytes, the cytotoxicity to the target cells and the survival time in vivo are critical for antitumor efficacy. IL-15 has been demonstrated to extend the lifetime of T lymphocytes in vitro to more than half a year without any exogenous cytokines. 26 Coexpression of IL-15 in CAR-modified T lymphocytes significantly enhanced the killing activities and survival time of the transferred T lymphocytes. 27 However, the coexpression of IL-15 and CAR in T lymphocytes by the internal ribosome entry site or other components often causes a discrepancy of expression of the CAR and IL-15. In addition, after reinfusion of the modified T lymphocytes, the benefits that are associated with the paracrine and autocrine effects of IL-15 will be blocked once the modified T lymphocytes are regulated by inhibitory regulatory T cells, which commonly occurred in previous studies. 28, 29 We therefore expressed IL-15 in T lymphocytes to enhance the cytotoxicity of V-1 CAR to VEGFR-1 þ tumor cells. As shown in Figure 1f , IL-15 secretion was determined and the amount of IL-15 was substantially higher than the lymphocytes that coexpressed CAR and IL-15. (ref. 27) IL-15-expressing T lymphocytes increased the cytotoxicity of V-1 CAR-modified T lymphocytes to A549 cells, which expressed a moderate level of VEGFR-1 (Figure 4) . At a high E:T ratio, the difference was not significant as the non-specific killing activity of T lymphocytes affected the efficacy. Figure 5b . In the V-1 þ IL-15 group, the data indicated that half of the mice (n ¼ 6) were tumor-free. This finding suggests that IL-15-expressing T lymphocytes can augment the inhibitory efficacy of the V-1 CAR-modified T lymphocytes on tumor formation. In addition, these data also indicate that cytokines are essential for the antitumor capacity of the modified T lymphocytes in vivo.
On the basis of these results, we established a new strategy to evaluate the inhibitory ability of V-1 CAR-modified T lymphocytes on tumor metastasis. On days 3, 10 and 17 after an intravenous injection of 1 Â 10 6 A549 cells, an equal amount of V-1 CARmodified T lymphocytes was administered intravenously. After the infusion of the T lymphocytes, 5 Â 10 4 recombinant human IL-2 (rhIL-2) was administered intraperitoneally for 3 days, two times per day. The schedule of this strategy emphasized the importance of cytokines in adoptive cell therapy, assigned multiple infusions of modified T lymphocytes and established a metastatic model, in which the modified T cells have an increased opportunity to The effectiveness of IL-15 is likely to be covered by IL-2 because these two cytokines share the same gc receptor and IL-2 has the priority to bind the receptor. 25, 30 The histochemical analysis of the lungs, 35 days after tumor challenge revealed similar outcomes that were in accordance with the survival analysis (Figure 5d ). V-1 CAR plus IL-15-modified T lymphocytes effectively inhibited the metastasis of A549 tumor cells as there is not any detected metastatic nodule. In the V-1 CAR group (n ¼ 5), only one nodule was detected between two bronchi (Figure 5d , V-1 panel, black arrow head). In the other groups, numerous nodules could be detected, especially in the groups without T lymphocytes infusions (No Tc and No Tc (IL-2) groups). These data indicated that V-1 CAR-modified T cells effectively inhibited the metastasis of tumor in the presence of essential cytokines and T lymphocytes that expressed IL-15.
V-1 CAR-modified T lymphocytes inhibit the tube formation of primary HUVECs
During the progression of tumor growth, neovascularization have a pivotal role in the supply of nutrients. In this process, the biological activities of endothelial cells mainly define the angiogenesis. To determine whether V-1 CAR-modified lymphocytes could affect the angiogenesis, we evaluated the impact of V-1 CAR-modified T lymphocytes on the tube formation of primary HUVECs in vitro. As shown in Figure 3b , primary HUVEC is likely more sensitive to the cytotoxicity elicited from V-1 CAR-modified T lymphocytes. In the Matrigel angiogenesis assay, we then selected a lower E:T ratio to investigate the inhibitory ability of V-1 CAR-modified T lymphocytes on tube formation. Three E:T ratios were selected in this assay as shown in Figure 6 . When the number of primary HUVECs and V-1 CAR-modified T lymphocytes was equal, the tube-formation process was rarely impacted compared with T lymphocytes modified with the control plasmid (Blank Vector). At a higher E:T ratio (10:1), tube formation is both obviously impaired in the V-1 CAR-modified T lymphocytes treated group and Blank Vector group due to the vulnerability of HUVECs to the non-specific cytotoxicity from the T lymphocytes. At the ratio of 5, we found that V-1 CAR-modified T lymphocytes more efficaciously inhibited the tube formation of primary HUVEC (Po0.05) (Figures 6a and b) . These data suggest that V-1 CAR-modified T lymphocytes have the potency of angiogenesis inhibition.
DISCUSSION
Decades of focused development of therapies that target VEGF/VEGFRs has benefited patients with solid tumors as the therapeutic implication of tumor angiogenesis was recognized. 31 Bevacizumab, a monoclonal antibody to VEGF, however, has been revoked to be administrated for patients with breast cancer because it did not extend the survival time of the patients. In addition to the modest efficacy of other anti-angiogenesis drugs, therapies that block the VEGF/VEGFR axis are being reconsidered. 32 In this study, we redirected T lymphocytes with VEGFR-1 specificity by CAR modification. The modified T lymphocytes demonstrated effective inhibition of tumor growth and metastasis. The direct cytotoxicity elicited by the modified T lymphocytes can overcome many pitfalls confronted with conventional therapies that block VEGF/VEGFRs axis. Firstly and most importantly, the direct killing of activated endothelial cells and tumor cells by the V-1 CAR-modified T lymphocytes can overwhelm the compensatory pathways that are resistant to the anti-angiogenesis therapies. Various mechanisms have been developed to address the ineffectiveness of anti-angiogenesis therapies. Many compensatory angiogenic factors, which are produced after VEGF-targeted therapy, are involved in the resistance to the therapy. 33 The cytotoxicity induced by the modified T cells directly kills endothelial cells via VEGFR-1 expression. The compensatory mechanisms, including the indicated angiogenic factors and pathways activated by tumor microenvironment, 34, 35 unlikely work in the cytotoxic T-lymphocytes-based cell therapy. Second, due to their capacity to kill tumor cells, the modified T lymphocytes may overcome the resistance that is developed by tumor cells. Tumors are heterogeneous and the tumor blood vessels are surrounded by tumor and stromal cells. Traditional anti-angiogenesis therapies through the blockade of VEGF/VEGFR axis often lead to a reduced supply of oxygen, which finally render tumor cells hypoxic. As a result, the hypoxia induces other proangiogenic pathways to promote angiogenesis, leading to a modest responsiveness to these therapies. 36 Third, CAR-modified T lymphocytes can inhibit metastasis induced by hypoxia in antiangiogenesis strategies. Previous studies indicated that the hypoxia induced by blockade of angiogenesis increases the metastasis and invasion of tumor cells. 37, 38 The CAR-modified T lymphocytes are more prone to killing the metastatic tumor cells as they have an increased exposure to CAR-modified T lymphocytes once metastasis occured. In this study, the efficacious inhibition of metastasis was determined, especially in the presence of essential cytokines. (Figures 5b and c) .
For adoptive cell therapy, the cytotoxicity and survival of the transferred modified T lymphocytes are vital for antitumor efficacy. In previous studies, costimulatory factors were incorporated into the CAR construct. Cytoplasmic of the costimulatory molecules, such as CD28, 4-1BB (CD137) and OX-40, were inserted before CD3 z domain. These signals effectively increased the cytokine release, lytic capacity and extended survival and proliferation of the CAR-modified T lymphocytes, which consequently improved antitumor potency, as well as the in vivo persistence, infiltration and proliferation of the transferred T lymphocytes. 9, 39, 40 In some cases, the CD28 costimulatory domain failed to enhance the potency of the CAR-modified T lymphocytes. 41 The 4-BB cytoplasmic domain could not improve the antitumor efficacy although the persistence of the transferred lymphocytes has been extended. 9 Most importantly, severe adverse effects have occurred in patients in clinical trials mainly due to 'cytokine storm' that was induced by the costimulation. 42, 43 In this study, we did not incorporate the costimulatory domain in to our CAR construct due to considerations of the adverse effect, especially when an antigen, such as VEGFR-1 here, has a low expression on normal tissues.
Excluding the costimulatory signals, there are many strategies to enhance the effectiveness of the transferred lymphocytes. Exogenous cytokines, including IL-2, IL-15 and IL-7, have increased the proliferation and survival of the transferred lymphocytes. 29, 44 The coexpression of cytokines with CAR in T lymphocytes improved the efficacious capacity. 27 Myeloablation also improved the efficacy of adoptive cell therapy. 45 In our study, we first documented that lymphocytes expressing IL-15 enhanced the anti-metastasis ability that was mediated by V-1 CAR-modified T lymphocytes (Figures 4 and 5) . IL-15 has long been demonstrated to extend the survival of natural killer and CD8 þ T lymphocytes and improved their cytolytic capacity. Compared with exogenously administered IL-15, T lymphocytes expressing IL-15 may have a long half-life in vivo as the T lymphocytes modified to express IL-15 can survive more than 6 months without any exogenous cytokines. 26 In our study, the T lymphocytes that express IL-15 increased the lytic capacity of CAR-modified T lymphocytes to the target cells and enhanced the efficacy of tumor formation and metastasis. Secreted IL-15 might contribute to these improvements. Other underlying mechanism, if there is any, is unknown. Compared with the adoptive transfer of CARmodified T lymphocytes that coexpress IL-15 where the IL-15 from autocrine and/or paracrine is consumed by the CAR-modified T lymphocytes with priority, 27 it is unknown whether the secreted VEGFR-1 specificity redirection of T lymphocytes W Wang et al IL-15 in our coinfusion strategy will firstly be ligated by CAR-modified T lymphocytes. In this study, however, the extent of the enhanced antitumor efficacy by T lymphocytes expressing IL-15, in vivo, is limited. This might be due to, (i) transient expression of IL-15 does not produce long term and enough IL-15 for the CAR-modified lymphocytes; (ii) less possibility of colocalization of the CAR-modified T cells and IL-15 expressed T lymphocytes. Viral vectors have been exploited to redirect the specificity of T lymphocytes because these vectors are an efficient tool for the genomic integration of interested genes. The risk of insertional mutagenesis has impeded the application of viral vectors. 46 Additional strategies stably integrated the interested gene in T lymphocytes have been developed, but with a lower efficiency. 47 In chronic lymphoid leukemia patients, lentivirally modified T lymphocytes with CD19 specificity proliferated more than 1000-fold, efficiently cleared CD19 þ leukemia cells and became memory T lymphocytes after reinfusion. Normal B cells with CD19 expression were also cleared and the modified T lymphocytes infiltrated into bone marrow where the pre-B cells were impaired. 6, 7 These findings demonstrated the efficacious removal of cancer cells by the T lymphocytes genetically modified by viral vectors, and emphasized the necessity to minimize side effects. In fact, tumor antigen receptor is not exclusively expressed on cancer cells. It is urgent to remove the CARmodified T lymphocytes to avoid the engagement of the CAR with the antigens on normal tissue, which leads to severe adverse effect. Alternatively, redirection of T lymphocytes by transient modification prevents these side effects and maintains the antitumor efficacy as presented in our study. First, transient modification with non-viral tools minimizes concerns regarding insertional mutagenesis. Second, in transiently modified T lymphocytes, expression of the CAR is gradually reduced, which prevent the sustained impairment of the normal tissue with a low expression of the antigen once the cancer cell is cleared. Third, antitumor capacity will not be impeded because multiple reinfusions compensate for the reduced CAR expression. 22 Our study provided CAR-modified T lymphocytes with VEGFR-1 affinity for adoptive cell therapy. The modified T lymphocytes demonstrated efficient inhibition of tumor formation and metastasis. This novel anti-angiogenesis strategy may compliment the conventional anti-angiogenesis therapy. Our data provide the rationale for the clinical translation of V-1 CAR-modified T lymphocytes.
MATERIALS AND METHODS
Construction of CARs with VEGFR-1 specificity
The signal peptide sequence of human IL-2 was added to the scFv with VEGFR-1 affinity using PCR. The transmembrane domain of the CD4 and CD3-z sequences were directly synthesized de novo from GenScript (Piscataway, NJ, USA). The IgG1 Fc sequence was cloned from the pFusehIgG1-Fc1 plasmid (Invitrogen, Life Technologies, Shanghai, China). The three sequences were spliced using overlapping PCR to form the V-1 CAR. Finally, the V-1 CAR was inserted into a pmaxCloning vector using NheI and BglII enzymes. The sequence was confirmed by sequencing and was deemed pmax-V-1 CAR. Similarly, the human IL-15 gene was inserted into the pmaxCloning vector, and the confirmed sequence was pmax-IL-15.
Cell culture
Peripheral blood mononuclear cells were obtained from voluntary donors with their consent. All of the procedures of the experiments were approved by the Ethics Committee of the State Key Laboratory of Biotherapy. Peripheral blood mononuclear cells were stimulated with an anti-CD3 antibody, 1 mg ml À 1 , in AIM-V medium (Invitrogen) and supplemented with 300 IU ml À 1 rhIL-2. The medium was refreshed every 3 days. When the CD3-positive cells reached more than 95% (as determined by flow cytometry), the cells were ready for the experiments and the culture medium was replaced with AIM-V medium supplemented with 300IU ml À 1 rhIL-2. Tumor cells, including MDA-MB 231, A549 and Hela cell lines, all purchased from ATCC, were cultured in Dulbecco's Modified Eagle's Medium (DMEM, GIBCO, Life Technologies) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U ml À 1 penicillin and 100 mg ml À 1 streptomycin. Primary HUVECs were separated as previously described. 48 HUVECs were cultured in M200 medium (GIBCO), which was supplemented with Low Serum Supplementary Cytokine (LSSC, GIBCO), 100 U ml À 1 penicillin and 100 mg ml À 1 streptomycin.
Electroporation of T lymphocytes
T lymphocytes were transfected with the intended plasmid by Nucleofector II (Lonza, Cologne, Germany) using the Amaxa Human T cells Nucleofector Kit, VPA-1002 (Lonza, Germany). The transfection procedure was performed as previously described. 22 Briefly, 5-10 Â 10 6 T lymphocytes were suspended in 100 ml transfection buffer and transferred into the electroporation cuvette. Program V-024 was selected for high transfection efficiency, and U-014 was selected for high viability. In this study, we selected program U-014 for the transfection if there was no special indication. After electroporation, T lymphocytes were pipetted in prewarmed AIM-V medium. Sixteen hours after transfection, the modified T lymphocytes were ready for adoptive transfer and other experiments. The transfection efficiency was evaluated by the fluorescent counts after pmax-green fluorescent protein transfection. A polyclonal goat anti-human CD3 z antibody (Abcam, Hong Kong, China) was used to detect the expression of V-1 CAR. The IL-15 expression level in the supernatant of the media was detected by a Human IL-15 ELISA Ready-Set-Go Kit (eBioscience, San Diego, CA, USA) according to the manual.
Flow cytometry
The expression levels of VEGFR-1 on HUVEC and tumor cell lines were examined using flow cytometry. Briefly, 10 ml PE conjugated VEGFR-1 antibody (Monoclonal Anti-human VEGF R1/Flt-1 Phycoerythrin (R&D, Minneapolis, MN, USA)) was added into 1 Â 10 5 cells that was suspended in 25 ml phosphate-buffered saline. 
Cytotoxicity assay
To determine the cytotoxicity of V-1 CAR-modified T lymphocytes to target cells, a standard 51 Cr release assay was performed to examine the cytolytic percentage using a different effector cell: target cell ratio (E:T ratio) as described previously. 49 Phenotypically, effector and target cells were stained with propidium iodide (50 mg ml À 1 ) solution containing 0.1% Triton X-100. The lymphocytes and target cells could be differed under fluorescent microscope because their nuclear size is varied.
Evaluation of the inhibitory capacity of the modified T lymphocytes on tumor growth, formation and metastasis
To evaluate the inhibition of tumor growth, we established the tumor model by inoculation of 5 Â 10 6 A549 subcutaneously cells in NOD-SCID BALB/c mice (n ¼ 5, per group). Until the xenografts were palpable, a single dose of 1 Â 10 7 modified T cells were infused intraperitoneally. Tumor volume (determined by the formula, 0.5 Â long diameter Â short diameter 2 ) was measured each 3 or 4 days. To examine the effect of V-1 CARmodified T lymphocytes on tumor formation, 1 Â 10 5 A549 cells were coinoculated subcutaneously with 1 Â 10 6 V-CAR-modified T lymphocytes in NOD-SCID BALB/c mice. Tumor-free percentage was calculated as follows: number of mice without palpable tumors/total number of mice. In the CAR þ IL-15 group, 1 Â 10 6 V-1 CAR-modified T lymphocytes and an equal number of T lymphocytes that expressed IL-15 were coinoculated with the A549 tumor cells. In the metastasis experiment, 2 Â 10 6 A549 cells suspended in 100 ml phosphate-buffered saline were intravenously injected into the tail vein. Three days later, 5 Â 10 6 V-1 CAR-modified T lymphocytes were infused, intravenously, and 5 Â 10 4 U rhIL-2 was administered introperitoneally for 3 days, two times per day. The infusion was repeated weekly for 2 weeks, and rhIL-2 was administered post-infusion. In total, three infusions of the modified T lymphocytes were performed on every mouse. In the CAR þ IL-15 group, the mice received 2 Â 10 6 V-1 CAR-modified T lymphocytes and 2 Â 10 6 T lymphocytes that expressed IL-15. Pulmonary metastatic nodules were detected by H&E staining of the lungs in each group of mice.
Matrigel tube formation assay
To evaluate the effect of V-1 CAR-modified T lymphocytes on angiogenesis, a tube formation assay with primary HUVECs was performed as previously described. 50 Briefly, 2000 HUVECs were cocultured with 2000, 10 000, and 20 000 V-1 CAR-modified T lymphocytes in 96-well plates coated with Matrigel (BD). Twenty-four hours later, capillary-like tubes were photographed, and the total length of the tubes was quantified using Image-Pro Plus software (Media Cybernetics).
Statistical analysis
The data were presented as the mean ± s.d., To assess the statistical significance of the differences, a Student's t-test was performed. P-values o0.05 were considered significant.
